标题
Targeting mTOR in Pancreatic Ductal Adenocarcinoma
作者
关键词
-
出版物
Frontiers in Oncology
Volume 6, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2016-04-25
DOI
10.3389/fonc.2016.00099
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing
- (2016) Vicente Valero et al. ANNALS OF SURGERY
- Multi-Omic profiling (MoP) for patients (pts) with pancreatic cancer (PDA): Initial results of the Know Your Tumor (KYT) initiative.
- (2016) Michael J. Pishvaian et al. JOURNAL OF CLINICAL ONCOLOGY
- The Know Your Tumor (KYT) initiative: A national program of multi-omic molecular profiling (MoP) for patients (Pts) with pancreatic cancer (PDA).
- (2016) Anitra Engebretson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
- (2015) S. Kordes et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms
- (2015) Vincenza Cifarelli et al. DIABETES
- A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling
- (2015) Bo Kong et al. GUT
- mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer
- (2015) Feng Wei et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2
- (2015) H. P. Soares et al. MOLECULAR CANCER THERAPEUTICS
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells
- (2015) Shu-Feng Zhou et al. Drug Design Development and Therapy
- Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells
- (2015) Shu-Feng Zhou et al. Drug Design Development and Therapy
- Pancreatic Adenocarcinoma
- (2015) David P. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells
- (2014) Hai-zhou Lou et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma
- (2014) Wesley K. Utomo et al. CANCER LETTERS
- Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
- (2014) B. Alagesan et al. CLINICAL CANCER RESEARCH
- Targeting mTOR dependency in pancreatic cancer
- (2014) Douglas C Morran et al. GUT
- Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts
- (2014) Stephan Kruger WORLD JOURNAL OF GASTROENTEROLOGY
- Diabetes, pancreatic cancer, and metformin therapy
- (2014) Jun Gong et al. Frontiers in Physiology
- Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells
- (2014) Enrique Rozengurt Frontiers in Physiology
- Recent progress in pancreatic cancer
- (2013) Christopher L. Wolfgang et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Selective Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer
- (2013) Stefan Eser et al. CANCER CELL
- mTOR kinase inhibitors as potential cancer therapeutic drugs
- (2013) Shi-Yong Sun CANCER LETTERS
- The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma Cells
- (2013) T. J. Hayman et al. CLINICAL CANCER RESEARCH
- Biopsies: next-generation biospecimens for tailoring therapy
- (2013) Mark Basik et al. Nature Reviews Clinical Oncology
- Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells
- (2013) Heloisa P. Soares et al. PLoS One
- Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells
- (2013) Zhi-Jun Dai et al. Drug Design Development and Therapy
- Pancreatic Ductal Adenocarcinoma
- (2012) Ioannis T. Konstantinidis et al. ANNALS OF SURGERY
- The mTOR Signalling Pathway in Human Cancer
- (2012) Helena Pópulo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Early Mortality Risk Score: Identification of Poor Outcomes Following Upfront Surgery for Resectable Pancreatic Cancer
- (2012) Charles C. Hsu et al. JOURNAL OF GASTROINTESTINAL SURGERY
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy
- (2011) S. T. Kim et al. MOLECULAR CANCER THERAPEUTICS
- PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB–Cytokine Network
- (2011) Haoqiang Ying et al. Cancer Discovery
- Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
- (2010) Milind M Javle et al. BMC CANCER
- Metformin, Independent of AMPK, Inhibits mTORC1 in a Rag GTPase-Dependent Manner
- (2010) Adem Kalender et al. Cell Metabolism
- Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer
- (2010) E. Rozengurt et al. CLINICAL CANCER RESEARCH
- Metformin: Taking away the candy for cancer?
- (2010) Mathilde Jalving et al. EUROPEAN JOURNAL OF CANCER
- mTOR Inhibitor Treatment of Pancreatic Cancer in a Patient With Peutz-Jeghers Syndrome
- (2010) Heinz-Josef Klümpen et al. JOURNAL OF CLINICAL ONCOLOGY
- Metformin Disrupts Crosstalk between G Protein-Coupled Receptor and Insulin Receptor Signaling Systems and Inhibits Pancreatic Cancer Growth
- (2009) K. Kisfalvi et al. CANCER RESEARCH
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
- The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
- (2008) I Ben Sahra et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started